Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986288 + nivolumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BMS-986288 + nivolumab is an investigational **combination immunotherapy** comprising BMS-986288, a probody monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and nivolumab, a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1). BMS-986288 is a modified version of ipilimumab (Yervoy), designed as a probody (masked antibody) to specifically activate in the tumor microenvironment to reduce off-tumor toxicity. Nivolumab (Opdivo) acts by inhibiting PD-1, thereby promoting T-cell-mediated anti-tumor immunity. The combination is being evaluated for the treatment of various advanced solid tumors, including colon cancer and other malignancies, to assess safety, tolerability, and preliminary efficacy[2][7].
- Other names
- BMS-986288 + Opdivo
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BMS-986288 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986288 + nivolumab.